AK Medical (1789.HK): China Cut Hip Prices 80 Percent, and the Company That Won Bought Back Its Own Stock

In 2021 the Chinese government cut the price of an artificial hip by roughly 80 percent in a single tender. Not over a decade of competition. In one round of centralised procurement, by decree.

Almost every company in the industry would describe that as a catastrophe, and for the multinationals that had owned the premium tier it was. $1789.HK, AK Medical won the largest allotment, more than 15 percent of year one. Five years later, in March 2026, it announced a US$40 million buyback and over the following 180 days repurchased 3.66 percent of its shares outstanding, while insiders bought in the same window. The market capitalisation is US$683 million.

A company that emerges from an 80 percent price cut with more volume, more cash and fewer shares outstanding is worth understanding properly, because the mechanism is not obvious and the risk that comes with it is real.

What the Company Actually Makes

When an 80-year-old in Beijing can no longer walk, a surgeon opens the hip, removes the worn joint, and screws in a metal stem, a ball, and a cup. AK Medical makes those parts.

It is China's largest domestic joint brand by volume, with more than 70 Class III registrations, a presence in around 3,500 hospitals, and over 1.2 million implants placed. Class III is the highest regulatory category in China, reserved for devices that are implanted and life-sustaining, and each registration is a multi-year process. Seventy of them is not a product line, it is a decade of regulatory work that a new entrant would have to repeat from the beginning.

The Moat Is a Surgeon's Habit

The competitive advantage here is not the metal. Any competent manufacturer can produce a titanium stem. The advantage lives in the hands of the surgeon.

Every implant system comes with its own instrument tray, its own sequence of steps, its own broaches and reamers and sizing logic. A surgeon who has done a thousand procedures with one system has that sequence in muscle memory. Switching means relearning it, and relearning it happens on live patients. The cost of the switch is not measured in money, it is measured in the elevated risk carried by the first several dozen operations.

Once trained, surgeons rarely switch. The switching cost is not paid by the hospital's finance department. It is paid by a patient.

That is about as durable a switching cost as exists in any industry, because no rational surgeon accepts avoidable risk to save a procurement department a modest sum. It is the same shape we described in our explainer on what an economic moat actually is: the strongest switching costs are the ones where the person who would have to bear the pain of switching is not the person who would capture the saving.

At the top end the lock is tighter still. For bone tumour and revision cases, where the anatomy is destroyed and a standard implant will not fit, AK's patient-specific 3D-printed titanium implant is often the only domestic option available. In those theatres there is no comparison shopping, because there is nothing to compare.

The Porous Lattice, Applied to a Hospital System

AK's 3D-printed implants have a porous lattice structure. Bone grows into the gaps, so over months the implant and the skeleton become mechanically continuous. It is an elegant piece of engineering, and it is also the best available description of the company's commercial strategy.

AK has done the same thing to China's hospital system. A decade of clinical data gives surgeons published evidence to cite. More than 600 patents make the technology difficult to copy directly. And the K3 surgical robot completes the structure: once a hospital installs a robot built around AK's implant geometry, AK implants become the default consumable for every procedure that robot performs.

Each of those is ordinary on its own. Together they function like the lattice: the company grows into the institution, and removing it stops being a purchasing decision and starts being a surgical one.

How a Price Cut Became a Market Share Gift

Before 2021, Stryker, worth more than US$130 billion, and Zimmer Biomet, worth more than US$20 billion, owned the premium tier of Chinese orthopaedics. They had the brands, the surgeon relationships and the pricing.

Then Beijing introduced volume-based procurement for joints. The state aggregates national demand, runs one tender, and allocates volume to the winning bidders. Joint prices fell by roughly 80 percent, and the volume went to domestic bidders. AK won the largest single slice, over 15 percent in year one.

What makes this Counter-Positioning in Hamilton Helmer's sense is that the incumbents could not simply match the price. A multinational that accepts Chinese tender pricing has to explain that price to every other health system it sells into, and it carries a global cost structure, a compliance apparatus and a margin expectation built for premium pricing. The rational response for them was to concede the volume rather than damage the rest of the business. That reluctance is not a failure of management, it is the correct decision given their position, and it is exactly what makes the new entrant's advantage stick.

The domestic field that remains is real but manageable: Chunli at around US$0.4 billion, plus Weigao and MicroPort. AK is the largest by volume, and in a system where scale determines cost position and cost position determines tender outcomes, that ordering matters more than it would in a normal market.

Overseas Is the Escape Hatch

If your domestic price is set by decree, the most valuable revenue you can own is revenue that is not.

Overseas sales are 22 percent of the total today, and they have compounded at around 40 percent a year since 2020, into more than 40 countries. Management explicitly credits “rapid expansion in overseas sales and intelligent devices” for recent performance. Ten K3 surgical robots were sold between January and May 2026, five of them abroad.

Those robot placements are the part worth watching most closely. A robot sale is small revenue on its own, but each installation is an annuity: it pulls AK implants through for years, and it does so in markets where the price is negotiated commercially rather than administratively. Every point of overseas mix reduces the share of the business exposed to the next tender, and does so permanently.

Capital Return: A Dividend Up 64 Percent, and Two Signals at Once

The capital return record is unusually clear for a Chinese mid-cap:

• The final dividend rose 64 percent in a year to US$0.015 per share, a yield of about 2.0 percent.
• A US$40 million buyback launched in March 2026, under which the company repurchased 3.66 percent of shares outstanding over 180 days. That is real execution, not an announcement.
• Insiders bought in the same window.

The combination of a company retiring its own stock and the people who run it buying with personal money at the same time is the pattern we track deliberately, because the two signals corroborate each other in a way neither does alone. A buyback can be a mechanical use of surplus cash; personal purchases at the same prices are harder to explain away. We wrote about why that overlap is worth isolating in the double signal.

It also settles the most important empirical question about volume-based procurement. An 80 percent price cut either destroys cash generation or it does not. A company that can fund a rising dividend and buy back nearly 4 percent of itself within five years of the cut is telling you that the cost position absorbed it.

The MoatMap Scorecard: Q77 V64 M65, StockRank 97

Here is the AK Medical MoatMap StockRank:

• Quality: 77/100. Strong. Market leadership by volume, 70 plus Class III registrations, a genuine switching cost, and margins that survived a national price reset.
• Value: 64/100. Comfortably above the midpoint at 16.5 times trailing earnings and about 12 times forward. For a market leader growing overseas at 40 percent a year, that is not a demanding multiple.
• Momentum: 65/100. Solid rather than spectacular, which given the sector is arguably the healthier reading.
• Composite StockRank: 97/100. Very high, and it comes from balance rather than from one extreme factor. Nothing here is weak, which is what pushes a set of good scores into a top-decile composite.

A profile like this, with no single dominant factor and no weak one, is the configuration our guide to factor investing describes as the most robust, because it does not depend on one factor continuing to work. The wider market setup sits in Best Hong Kong Stocks 2026 and Best Chinese Stocks 2026, where the healthcare cluster that survived the procurement squeeze appears repeatedly.

The Question Worth Sitting With

Roughly three quarters of sales are domestic, and most of that is priced by a government tender that resets by decree. Each round is binary in a way that ordinary competition never is. Win, and you keep 3,500 hospitals. Lose, and they vanish, not gradually over several years of share drift but at the moment the allocation is published.

So the question that decides this investment is uncomfortable and unavoidable:

If the regulator, and not the customer, picks the winner, whose moat is it?

The bull answer is that the regulator is not choosing arbitrarily. It selects on cost, capacity and clinical track record, and those are precisely the attributes AK has spent a decade accumulating. The surgeon habit, the installed robots and the 600 patents are not erased by a tender, they are the reasons AK keeps winning tenders. The overseas business, at 22 percent and compounding at 40 percent a year, is the deliberate hedge, and each year it grows the binary risk covers less of the company.

The bear answer is that a moat granted by policy can be withdrawn by policy, and that surgeon loyalty is only decisive when the surgeon gets to choose. In a centralised tender the hospital receives what the allocation delivers. A rival that bids more aggressively in one round could take volume that a decade of clinical relationships did not protect. As one reader put it after the original thread, China did to orthopaedics what it did to pharmaceuticals: procurement destroys pricing and consolidates share toward the lowest-cost producer. Being the lowest-cost producer today is not a permanent condition.

Both readings can be held at once, and the scorecard does not resolve them. At 12 times forward earnings the market is not pricing AK as a company with a permanent franchise; it is pricing a good business with a policy variable attached. That is a defensible price for the setup, which is roughly what a Value score of 64 is saying.

Companion Reading

AK Medical sits inside our China healthcare and policy-exposed clusters with three close neighbours:

• Chaoju Eye Care (2219.HK) is the closest twin: Chinese healthcare, real clinical franchise, a fortress balance sheet, and the same central tension between operational quality and government pricing pressure.
• Greentown Management (9979.HK) for the broader Chinese question in a different industry: what a genuinely good business is worth when policy, rather than the customer, sets the terms.
• Mi Technovation (5286.KL) for the switching cost in another industry entirely: being qualified into a customer's process, where the barrier is the risk of changing rather than the price of staying.

The Bottom Line

AK Medical is the rare case of a company that was handed an 80 percent price cut and came out larger. The mechanism was Counter-Positioning: multinationals with a global price umbrella could not follow the tender down without damaging everything else they sell, so they conceded the volume, and the largest domestic manufacturer took it. What holds the position now is a switching cost paid in patient risk rather than money, reinforced by 70 plus Class III registrations, more than 600 patents, a decade of clinical data, and a surgical robot that makes AK implants the default consumable wherever it is installed.

The evidence that the economics survived is in the capital returns: a dividend up 64 percent, a US$40 million buyback that retired 3.66 percent of the shares, and insiders buying alongside. The escape hatch is overseas, 22 percent of sales and compounding at 40 percent a year across 40 plus countries, and every point it gains shrinks the part of the business that a tender can reprice.

What no amount of analysis removes is the binary. Three quarters of revenue depends on winning rounds decided by the state, and each round is settled at once rather than gradually. A composite of 97 at 12 times forward earnings says the framework finds the risk fairly compensated today. For sizing a position where the business is strong and one external variable can reset it, our guide to reviewing your portfolio for weak spots is the right framework.

For the full breakdown including the procurement history, the segment economics, the robot strategy, the overseas build and the valuation walk, the AK Medical Deep Dive is the place to go.

This article is for informational purposes only and is not investment advice. The author may be long names covered on MoatMap.